Status:
COMPLETED
Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
End-stage Heart Failure
Cardiomyopathies
Eligibility:
All Genders
18-75 years
Brief Summary
The aim of this study is to evaluate the incidence of any hemocompatibility related adverse event (HRAE) after LVAD placement in patients responsive to a standard aspirin dose using point-of-care plat...
Detailed Description
Left Ventricular Assist Device (LVAD) therapy has become a well-established treatment option for end stage heart-failure either as a bridge to transplant or destination therapy. As previously reported...
Eligibility Criteria
Inclusion
- The participants will be recipients of the routinely used HeartMate 3 (Abbott, Abbott Park, IL) or HVAD (Medtronic Inc., Dublin, Ireland) system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria.
Exclusion
- Age: \<18 or \>75 years
- Inability to provide informed consent
- No ASA therapy
Key Trial Info
Start Date :
December 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 28 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06152562
Start Date
December 6 2021
End Date
November 28 2023
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090